-

Ademi & Fruchter LLP Continues to Investigate Claims of Securities Fraud against UnitedHealth Group Incorporated

MILWAUKEE--(BUSINESS WIRE)--Ademi & Fruchter LLP is investigating possible securities fraud claims against UnitedHealth (NYSE: UNH). The investigation results from inaccurate statements UnitedHealth made regarding its business operations and prospects.

Click here to join our investigation or to obtain additional information, or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you.

The investigation focuses on UnitedHealth’s recent revisions to its financial forecast for 2025, the resignation of CEO Andrew Witty and the suspension of full-year guidance. UnitedHealth has already admitted its recent performance has been “unusual and unacceptable,” and analysts are calling the revisions “really surprising” and caused by “executional errors.” Former CEO Stephen Hemsley will replace Witty and said on a call today, “I'm deeply disappointed and apologize for the performance setbacks we've encountered. Many of the issues standing in the way of achieving our goals as well as our opportunities are largely within our control. This includes pricing for the Medicare plans, as well as other areas.”

The investigation covers the period between April 2024 and May 12, 2025.

We specialize in securities fraud and shareholder litigation. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi & Fruchter LLP
Guri Ademi
3620 East Layton Ave.
Cudahy, WI 53110
Toll Free: (866) 264-3995
Fax: (414) 482-8001
www.ademilaw.com

Ademi & Fruchter LLP

NYSE:UNH

Release Versions

Contacts

Ademi & Fruchter LLP
Guri Ademi
3620 East Layton Ave.
Cudahy, WI 53110
Toll Free: (866) 264-3995
Fax: (414) 482-8001
www.ademilaw.com

More News From Ademi & Fruchter LLP

Shareholder Alert: The Ademi Firm Investigates Whether 89bio, Inc. is Obtaining a Fair Price for its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating 89bio (Nasdaq: ETNB) for possible breaches of fiduciary duty and other violations of law in its transaction with Roche. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. Shareholders of 89bio will receive $14.50 per share in cash at closing, plus a non-tradeable CVR to receive certain milestone payme...

Shareholder Alert: The Ademi Firm Investigates Whether Paramount Group Inc. Is Obtaining a Fair Price for Its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Paramount (NYSE: PGRE) for possible breaches of fiduciary duty and other violations of law in its transaction with a Rithm Capital. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. Shareholders of Paramount will receive $6.60 per fully diluted share in an all-cash transaction valued at approximately...

Shareholder Alert: The Ademi Firm Continues to Investigate Whether TEGNA Inc. is Obtaining a Fair Price for its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating TEGNA (NYSE: TEGNA) for possible breaches of fiduciary duty and other violations of law in its going-private transaction. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. Shareholders of TEGNA will receive $22.00 per share in an all-cash transaction valued at $6.2 billion, including TEGNA's net debt...
Back to Newsroom